PMID- 11302478
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20190915
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 12
IP  - 2
DP  - 2001 Mar
TI  - Accumulation of low molecular mass heparin during prophylactic treatment in 
      pregnancy.
PG  - 149-55
AB  - A history of thromboembolism is associated with an increased risk of new 
      thromboembolic events during pregnancy. Prophylaxis with heparin during pregnancy 
      implicates long-term treatment with daily injections with either unfractionated 
      heparin (UFH) or low molecular mass heparin (LMMH). Prolonged treatment with 
      heparin may result in endothelial absorption and drug accumulation. In order to 
      test this hypothesis, anti-FXa activity during pregnancy was measured in four 
      women allergic to conventional UFH, who were treated with LMMH (dalteparin; 
      Pharmacia). It was found that, at the commencement of treatment, it took more 
      than 8 days to reach a steady maximum peak value, located 3 h after the given 
      dose. One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa 
      for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37. The 
      implications of an elevated anti-FXa activity during pregnancy, especially during 
      the third trimester and at partus, are discussed. We present a reduced dose 
      regime near term and during delivery.
FAU - Bremme, K
AU  - Bremme K
AD  - Department of Woman and Child Health, Karolinska Institutet, Karolinska Hospital, 
      Stockholm, Sweden. katarina.bremme@ks.se
FAU - van Rooijen, M
AU  - van Rooijen M
FAU - Yu, A
AU  - Yu A
FAU - Blomback, M
AU  - Blomback M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/administration & dosage/*blood/*therapeutic use
MH  - Dalteparin/administration & dosage/*blood/*therapeutic use
MH  - Factor Xa Inhibitors
MH  - Female
MH  - Gestational Age
MH  - Heparin/adverse effects
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Thromboembolism/*prevention & control
MH  - Urticaria/chemically induced
MH  - Venous Thrombosis/drug therapy
EDAT- 2001/04/17 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/04/17 10:00
PHST- 2001/04/17 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/04/17 10:00 [entrez]
AID - 10.1097/00001721-200103000-00010 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2001 Mar;12(2):149-55. doi: 
      10.1097/00001721-200103000-00010.